LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

Начало・Списък с акции・Vaxart Inc

Vaxart Inc

Отворен

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

Ключови измерители
By Trading Economics
Приходи	6.8M -8.1M
Продажби	33M 72M
Марж на печалбата	-11.242
Служители	105
EBITDA	6.7M -5.4M

Дивиденти
By Dow Jones
Следващи печалби	19.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	45M 136M
Предишно отваряне	0
Предишно затваряне	0

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

0.4007 / 0.4252 Подкрепа & съпротива

Vaxart Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.02.2026 г., 22:53 ч. UTC

Придобивния, сливания и поглъщания

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23.02.2026 г., 22:36 ч. UTC

Печалби

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23.02.2026 г., 22:32 ч. UTC

Печалби

Woodside Energy Fiscal Year Net Profit Falls 24%

23.02.2026 г., 23:58 ч. UTC

Пазарно говорене

Печалби

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23.02.2026 г., 23:58 ч. UTC

Пазарно говорене

Печалби

Global Energy Roundup: Market Talk

23.02.2026 г., 23:47 ч. UTC

Пазарно говорене

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23.02.2026 г., 23:43 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23.02.2026 г., 23:41 ч. UTC

Придобивния, сливания и поглъщания

Crescent Capital Partners Owns 53% of ClearView Wealth

23.02.2026 г., 23:40 ч. UTC

Придобивния, сливания и поглъщания

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23.02.2026 г., 23:40 ч. UTC

Придобивния, сливания и поглъщания

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23.02.2026 г., 23:40 ч. UTC

Пазарно говорене

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23.02.2026 г., 23:40 ч. UTC

Придобивния, сливания и поглъщания

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23.02.2026 г., 23:39 ч. UTC

Придобивния, сливания и поглъщания

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23.02.2026 г., 23:31 ч. UTC

Печалби

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23.02.2026 г., 23:31 ч. UTC

Печалби

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23.02.2026 г., 23:28 ч. UTC

Печалби

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23.02.2026 г., 23:28 ч. UTC

Печалби

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23.02.2026 г., 23:28 ч. UTC

Печалби

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23.02.2026 г., 23:27 ч. UTC

Печалби

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23.02.2026 г., 23:24 ч. UTC

Пазарно говорене

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23.02.2026 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23.02.2026 г., 22:31 ч. UTC

Печалби

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23.02.2026 г., 22:24 ч. UTC

Печалби

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23.02.2026 г., 22:22 ч. UTC

Печалби

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23.02.2026 г., 22:22 ч. UTC

Печалби

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23.02.2026 г., 22:22 ч. UTC

Печалби

Viva Energy FY Underlying Ebitda A$700.9 Million

23.02.2026 г., 22:22 ч. UTC

Печалби

Viva Energy Final Dividend 3.94 Australian Cents/Security

23.02.2026 г., 22:21 ч. UTC

Печалби

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23.02.2026 г., 22:21 ч. UTC

Печалби

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23.02.2026 г., 22:20 ч. UTC

Печалби

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Сравнение с други в отрасъла

Ценова промяна

Vaxart Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Vaxart Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.4007 / 0.4252Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.